First‐in‐human phase 1 study of MK‐1248, an anti–glucocorticoid‐induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors
| Publication | Article in Cancer, published August 2020 |
|---|---|
| Authors | Ravit Geva, Mark Voskoboynik, Konstantin Dobrenkov, Kapil Mayawala, Jennifer Gwo, Richard Wnek,...[ show more ] |
This is the public page for a publication record in Dimensions, a free research insights platform that brings together information about funding, scholarly outputs, policy, patents and grants.
Loading metrics…